EUCTR2010-024273-38-GB进行中（未招募）1 期
Supplemental COrTicosteroids in Cirrhotic Hypotensive patients with suspicion of SepsIS. The SCOTCHIS trial - SCOTCHIS trial
niversity Hospitals of Leuven0 个研究点目标入组 356 人开始时间: 2017年4月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 356
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •All patients with known or recently diagnosed cirrhosis who
- •a) are admitted to the ICU because of persistent hypotension or
- •b) develop persistent hypotension while admitted to the ICU,
- •both secondary to proven or suspected infection, in both cases despite adequate fluid resuscitation and with need of norepinephrine (any dose) to maintain a mean arterial blood pressure > 60 mmHg or > 65 mmHg if accompanied with signs of organ hypoperfusion, are eligible for study entry. The diagnosis of cirrhosis is preferably made by histology or based on imaging and laboratory findings.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 339
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 17
排除标准
- •Patients receiving any vasopressor medication, initiated for septic shock, for more than 24 h prior to administration of study drug. Terlipressin initiated for treatment of hepatorenal syndrome or variceal bleeding is allowed.
- •Patients with known hypoadrenalism
- •Active GI bleeding (unless controlled for > 24 hours) or haemorrhagic shock.
- •Cardiogenic shock or severe cardiac dysfunction (CI <2 l/min/ m2)
- •Active uncontrolled hepatitis B infection
- •HIV infection
- •Evidence of advanced malignancy (except hepatocellular carcinoma within transplant criteria or non-melanocytic skin cancer). Malignancies in remission are allowed (for example: small cholangiocarcinomas treated and in theoretical response or breast and prostatic cancers in remission).
- •Therapy with any corticosteroid (oral or intravenous) in the last 3 months
- •Therapy with any other immunosuppressive drug in the last 3 months
- •Patients who received etomidate within the past 3 days
- •Severe acute alcoholic hepatitis (biopsy proven), because it compromises the survival
- •Chronic haemodialysis
- •Severe chronic heart disease (NYHA class III or IV)
- •Severe chronic obstructive pulmonary disease (GOLD III or IV)
- •Severe psychiatric disorder
- •Child-Pugh score C14 -15
- •SOFA score > 16 points at inclusion (SOFA is a score of severity of critically ill disease according to number and degree of organ failure)
- •Pregnant or breastfeeding women
- •Contraindications for systemic steroids
- •Refusal to consent
- •Patients who cannot provide prior informed consent and when there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent.
研究者
相似试验
进行中（未招募）
不适用
se of corticosteroids (ie. adrenal gland hormone) in the treatment of cirrhotic patients with suspected sepsis and low blood pressure compared to placeboEUCTR2010-024273-38-CZniversity Hospitals Leuven356
进行中（未招募）
1 期
se of corticosteroids (ie. adrenal gland hormone) in the treatment of cirrhotic patients with suspected sepsis and low blood pressure compared to placeboEUCTR2010-024273-38-BEniversity Hospitals Leuven356
终止
3 期
Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of SepsisLiver CirrhosisNCT02602210Universitaire Ziekenhuizen KU Leuven100
招募中
2 期
Study on Nasal Irrigation with Corticosteroid in patients with Chronic Sinusitischronic sinusitisnasal polyps.C08.460.692.752G03.015.500.703.500RBR-9j3d9zniversidade Federal de São Paulo - UNIFESP
进行中（未招募）
1 期
A randomised blinded placebo controlled trial of hydrocortisone in critically ill patients with septic shockSeptic ShockEUCTR2012-003158-10-IEThe George Institute for Global Health3,800